Eosinophilic Asthma
📧 Sign up to get email alerts when something new happens for Eosinophilic Asthma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma [Phase 3]
Phase 3 trial update for reslizumab in severe eosinophilic asthma in patients aged 12 and older; study terminated with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2018-08-29Clinical Trial Update: Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma [Phase 4]
Phase 4 trial update studying the impact of benralizumab on circulating dendritic cells in patients with severe eosinophilic asthma.
-
CLINICAL_TRIALS trial_result · 2016-06-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma [Phase 3]
Phase 3 trial evaluating reslizumab for eosinophilic asthma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2016-06-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma [Phase 3]
Phase 3 trial evaluating reslizumab for reducing asthma exacerbations in eosinophilic asthma completed with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-06-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma [Phase 3]
Phase 3 trial evaluating reslizumab at 0.3 or 3.0 mg/kg for eosinophilic asthma has been completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-06-06Clinical Trial Update: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma [Phase 3]
Open-label extension study assessing the long-term safety and efficacy of reslizumab (3.0 mg/kg) in eosinophilic asthma patients aged 12-75;…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: A Phase IIa Study of KHK4563 [Phase 2]
This update reports the completion of a Phase IIa study of KHK4563 in patients with uncontrolled and suspected eosinophilic asthma.